News

Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for Rinvoq (upadacitinib). Rinvoq, which is discovered and developed

Piramal Pharma (PPL), a subsidiary of Piramal Enterprises, has agreed to acquire 100% stake in Indian peptide APIs manufacturer Hemmo Pharmaceuticals, for $105.6m (INR7.75bn). Upon completion of the

Takeda Pharmaceutical Company has completed the previously announced sale of a portfolio of select over-the-counter (OTC) pharma products and non-core assets to Orifarm Group for $670m. The latest

Biotechnology company Amgen has agreed to acquire privately held biopharmaceutical company Rodeo Therapeutics. Under the deal, the company will acquire all Rodeo Therapeutics’ outstanding shares for a $55m

Merck has announced that the US Food and Drug Administration (FDA) has sent a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) for the approval

The US Food and Drug Administration (USFDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric

Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory

The European Medicines Agency (EMA) has validated Gilead Sciences’ marketing authorization application (MAA) for sacituzumab govitecan-hziy (SG) to treat advanced breast cancer. SG is an antibody and topoisomerase